ACADL and ADH1B are identified as key genes linking ketone body metabolism to immune dysregulation in osteoarthritis, offering potential new therapeutic targets.
ACADL and ADH1B link KBM abnormalities to immune dysregulation in the OA synovium. The nomogram enables the precise early diagnosis of OA, and progesterone and fomepizole are promising targeted therapies. These findings deepen the current understanding of OA pathogenesis and support the advancement of personalized treatments for clinical translation.
Li et al. (Tue,) studied this question.